Inherent BiosciencesUT-based company based in Salt Lake City, Utah, that is involved in commercializing a diagnostic for the emerging field of epigenetics biotech, has raised a Series A funding amount of undisclosed.
The round was led by Propel Bio Partners with participation from numerous stakeholders from patients to physicians and reproductive healthcare executives including Portfolia’s FemTech II Fund as well as Alliance of Angels Innovation Fund.
The funds will be used by the company to grow its pipeline and scale commercial operations, as well as to generate seminal data that will allow SpermQT to be added to the standard of care.
Inherent was co-founded by Kristin Brgaard, Chief Scientist Officer, and Andy Olson Chief Executive Officer. Inherent is an epigenetic platform that detects dysregulation in multiple genes and associated pathways. This platform will pioneer a new type of diagnostics, and therapeutics.
The company’s team of epigenetic technology innovators is made up of Dr. Larry Lipshultz, Professor of Urology and Chief of the Scott Department of Urology’s Division of Male Reproductive Medicine at Baylor College of Medicine; Dr. James Smith, Director of the Male Reproductive Health Center at UCSF; and Dr. Jim Hotaling, Director of the University of Utah Men’s Health program and current President of the Society for the Study of Male Reproduction, the premier society in the field.
Mera naam Sharma hai aur mujhe likhna kafi pasand hai. Jo bhi nya update entertainment, gaming, tech, etc ke related aata hai, mai use yahan cover karta hu.